Menu
  • Welcome
  • Resources
  • Webinars
  • News
  • Stats
  • Forums
  • Team
  • Contact
  • My Account
  • FR
  • Welcome
  • Resources
  • Webinars
  • News
  • Stats
  • Forums
  • Team
  • Contact
  • My Account
  • FR
home/Knowledge Base/Other Internal Medicine Specialties

Risk of Severe Presentation in Lupus Patients

96 views 0 05/03/2020 David Khalil

  1. Systemic lupus erythematosus is a probable risk factor to SARS-CoV-2 infection and severe COVID-19 presentation, independent of the immunosuppressive state from lupus therapy.
  2. In lupus patients, epigenetic dysregulation enhances viral entry into cells and induces pro-inflammatory changes resulting in a vicious cycle of cytokine response, and an increased possibility of cytokine storm.
    • SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors as an entry point into cells. ACE2 receptors are expressed by a methylation-sensitive gene on the X chromosome. Since lupus is a disease characterized by DNA demethylation, lupus patients show ACE2 hypomethylation, and thus probably overexpress ACE2 receptors (1.5 to 2-fold). ACE2 overexpression increases the likelihood of SARS-CoV-2 infection.
    • Viral infections increase oxidative stress, which are known to induce lupus flares, and thus further increase DNA methylation defects.
  3. Maintaining lupus remission is essential to reduce DNA demethylation and oxidative stress. Therapies such as chloroquine (CQ) and hydroxychloroquine (HCQ) have been demonstrated to prevent flares, reduce disease activity and organ damage and improve survival in lupus patients. In the context of possible shortages of CQ and HCQ amid speculations of their role in treating COVID-19, clinicians should consider prioritizing lupus patients with available stocks of CQ and HCQ.

 

The data concerning SARS-CoV-2 infection in systemic lupus erythematosus in this article is not based on prospective or controlled data, but on fundamental data previously observed with the pathophysiological processes in both systemic lupus erythematosus and SARS-CoV-2. 

Sources:

  1. Sawalha AH, Zhao M, Coit P, Lu Q. (April 7, 2020). Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol. https://doi.org/10.1016/j.clim.2020.108410. 
  2. Jakhar D, Kaur I. (April 8, 2020). Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med. https://doi.org/10.1038/s41591-020-0853-0. 
  3. Peschken CA. (April 8, 2020). Possible Consequences of a Shortage of Hydroxychloroquine for Lupus Patients Amid the COVID-19 Pandemic. J Rheumatol. https://doi.org/10.3899/jrheum.200395.
Tags:ACE2chloroquinehydroxychloroquinelupusSystemic lupus erythematosusRhumatologyCQHCQ

Was this helpful?

Yes  No
Related Articles
  • Is Testosterone a Good or a Bad Guy?
  • Considerations in the Management of Diabetes in the Pandemic Context
  • A Case of Immune Thrombocytopenic Purpura (ITP)
  • Understanding and Managing Kidney Injury
  • Prevention of Transmission in Haemodialysis Centres
  • Should We Discontinue ACE-I and ARB?
Other Internal Medicine Specialties
  • Risk of Severe Presentation in Lupus Patients
  • Is Testosterone a Good or a Bad Guy?
  • Considerations in the Management of Diabetes in the Pandemic Context
  • A Case of Immune Thrombocytopenic Purpura (ITP)
  • Understanding and Managing Kidney Injury
  • Prevention of Transmission in Haemodialysis Centres
View All 8  
Popular Articles
  • Acute Acro-Ischemic Lesions in Children
  • Insights About Reinfection and Immunization
  • What Is the Efficacy of Masks in Preventing Transmission?
  • Acral Lesions: What We Know
  • Rationale of Old Antimalarial Drugs Against New Pandemic
Specialties
  • Endocrinology
  • Anesthesiology
  • Cardiology
  • Dental Surgery
  • Dermatology
  • Emergency Medicine
  • ENT
  • Geriatrics and Palliative Care
  • Gastroenterology
  • Hematology
  • Infectious Diseases
  • Intensive Care
  • Neurology
  • OB-GYN
  • Oncology
  • Ophthalmology
  • Pediatrics
  • Pharmacology
  • Preventive Medicine
  • Protection of Healthcare Workers
  • Psychiatry
  • Public health
  • Other Internal Medicine Specialties
  • Radiology
  • Respirology
  • Stages of COVID-19 Infection
    • Presumption & Prevention
    • Screening & Diagnosis
    • Mild Infection
    • Moderate Infection
    • Severe Infection
    • Outcomes
  • Surgery
About How I Treat COVID-19

Our website is dedicated to helping healthcare professionals find accurate and up-to-date information about the best ways to manage and treat patients affected by the COVID-19 outbreak.

Navigation
  • Resources
  • News
  • Webinars
  • Forum
Useful Links
  • COVID-19 Protocols
  • Health Canada
  • WHO
  • CDC
Practice

  • Privacy Policy
  • Terms & Conditions
  • How I Treat Covid-19 © 2020 Made with ♥ by Mondien